← Product Code LOS · K981024 # QT DISPERSION AND T WAVE ANALYSIS PROGRAM (QT GUARD ANALYSIS SYSTEM) (K981024) _Marquette Medical Systems, Inc. · LOS · Oct 6, 1998 · CV · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K981024 ## Device Facts - **Applicant:** Marquette Medical Systems, Inc. - **Product Code:** LOS - **Decision Date:** Oct 6, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Review Panel:** CV - **Attributes:** Software as a Medical Device ## Intended Use QT Guard Analysis System is intended to be used in a hospital or clinic environment by competent health professionals. QT Guard Analysis System is intended to perform the analysis of simultaneously acquired 12-lead ECG for obtaining the measurements of QT interval dispersion and T wave complexity. QT-Guard Analysis Program is intended to provide only the measurements of the QT dispersion and T wave complexity and is not intended to produce any interpretation of those measurements or diagnosis. The QT dispersion and T wave complexity measurements produced by QT Guard Analysis System are intended to be used by qualified personnel in evaluating the patient in conjunction with patient's clinical history, symptoms, other diagnostic tests, as well as the professional's clinical judgment. QT Guard Analysis System is intended for adult patient populations. ## Device Story QT Guard Analysis System is a software program for 12-lead ECG analysis; inputs are simultaneously acquired 12-lead ECG signals; system calculates QT interval dispersion and T wave complexity; output is quantitative measurement data only; no automated diagnosis or interpretation provided; used in hospital or clinic environments by qualified health professionals; clinicians use output alongside patient history, symptoms, and other diagnostic tests to support clinical judgment; benefits include objective quantification of ECG parameters for patient evaluation. ## Clinical Evidence No clinical data provided. Performance validation based on bench testing, including requirements specification reviews, code inspections, and software testing. ## Technological Characteristics Software-based ECG analysis program; operates on simultaneously acquired 12-lead ECG data; provides quantitative measurements of QT dispersion and T wave complexity; intended for adult populations; developed using standard software quality assurance processes. ## Predicate Devices - Marquette 12SL Analysis Program ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ #### OCT 6 1998 # K981024 ## SECTION 2 - SUMMARY AND CERTIFICATION ## 2.1 510(k) Summary of Safety and Effectiveness This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. | Submitter: | Marquette Medical Systems
8200 W. Tower Avenue
Milwaukee, WI 53223
Telephone: (414) 355-5000
FAX: (414) 362-3553 | |---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact Person: | Kristin Pabst | | Device: | Trade Name: QT Dispersion and T wave Analysis
System (QT Guard Analysis System)
Classification Name: Computer, diagnostic, programmable | | Predicate Device: | Marquette 12SL Analysis Program | | Device Description: | QT Guard Analysis System is a software program for
measuring the QT interval dispersion and T wave complexity from
simultaneously acquired 12-lead ECG. | | Intended Use: | QT Guard Analysis System is intended to be used in a hospital
or clinic environment by competent health professionals | | | ♦ QT Guard Analysis System is intended to perform the analysis
of simultaneously acquired 12-lead ECG for obtaining the
measurements of QT interval dispersion and T wave complexity. | | | ♦ QT-Guard Analysis System is intended to provide only the
measurements of the QT dispersion and T wave complexity and it
is not intended to produce any interpretation of those
measurements or diagnosis. | | | ♦ The QT dispersion & T wave complexity measurements
produced by QT-Guard Analysis System are intended to
be used by qualified personnel in evaluating the patient in
conjunction with patient's clinical history, symptoms, other
diagnostic tests, as well as the professional's clinical judgment. | | | ♦ QT Guard Analysis System is intended for adult patient
populations. | | Technology: | QT Guard Analysis System employs technology similar to that
used in the predicate device. | {1}------------------------------------------------ Performance: The following quality assurance measures were applied: to the development of PHi-Res analysis. Requirements specification reviews, code inspections, software testing and laboratory tests of the QT Guard analysis. The results of these measurements demonstrated that QT Guard analysis is as safe, as effective, and performs as well as the predicate device, Marquette 12SL analysis program. {2}------------------------------------------------ Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 OCT 6 1998 Ms. Kristin Pabst Marquette Medical Systems, Inc. 8200 West Tower Avenue Milwaukee, WI 53223 Re : K981024 QT Dispersion and T Wave Analysis Program (QT-Guard Analysis System) Regulatory Class: III (three) Product Code: 74 LOS July 15, 1998 Dated: Received: July 16, 1998 Dear Ms. Pabst: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition TPDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {3}------------------------------------------------ #### Page 2 - Ms. Kristin Pabst This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html". Sincerely yours, Thomas J. Callehan Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ K981024 ### SECTION 11 - INTENDED USE STATEMENT 510(k) Number (if known): Unknown - 510(k) filed March 18, 1998 Device Name: QT Dispersion and T wave Analysis Program (QT Guard Analysis System) Indications For Use: QT Guard Analysis System is intended to be used in a hospital or clinic environment by competent health professionals. QT Guard Analysis System is intended to perform the analysis of simultaneously acquired 12-lead ECG for obtaining the measurements of QT interval dispersion and T wave complexity. QT-Guard Analysis Program is intended to provide only the measurements of the QT dispersion and T wave complexity and is not intended to produce any interpretation of those measurements or diagnosis. The QT dispersion and T wave complexity measurements produced by QT Guard Analysis System are intended to be used by qualified personnel in evaluating the patient in conjunction with patient's clinical history, symptoms, other diagnostic tests, as well as the professional's clinical judgment. QT Guard Analysis System is intended for adult patient populations. Rucuptim Use ✓ Mark Krainer (Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number **__** --- **Source:** [https://fda.innolitics.com/device/K981024](https://fda.innolitics.com/device/K981024) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com